Yeztugo / Sunlenca (Lenacapavir)

Lenacapavir is a medicine used to prevent HIV and, for some people, to treat HIV. It is usually given as a shot under the skin twice a year, after starting with a few pills. It works by blocking the protective shell the virus needs to copy itself.

Brand names:Sunlenca, Yeztugo
Medication

What people taking Yeztugo / Sunlenca (Lenacapavir) report

Every report comes from a Lived member, sent anonymously.

Have you tried Yeztugo / Sunlenca (Lenacapavir) for HIV Infection?

NameHow it went

About Yeztugo / Sunlenca (Lenacapavir)

What It's For

Lenacapavir is a long-acting HIV medicine given as an injection under the skin every six months. It is sold under two brands with different jobs. Yeztugo is used for HIV prevention, known as PrEP (pre-exposure prophylaxis). It lowers the chance of getting HIV through sex for adults and adolescents who weigh at least 35 kg (about 77 pounds) and are at risk of HIV. It is only for people who have tested negative for HIV. Other PrEP choices include daily pills such as Truvada (emtricitabine and tenofovir disoproxil fumarate) or Descovy (emtricitabine and tenofovir alafenamide), and Apretude (cabotegravir), an injection given every two months. Sunlenca is used to treat HIV in adults whose virus has become resistant to many HIV medicines and whose current treatment is failing or can no longer be used. It is always combined with other HIV medicines. Sunlenca tablets are also used for the first two days when someone switches to Bixlenvo, a separate once-daily pill that combines lenacapavir with bictegravir for adults whose HIV is already well controlled.

How It Works

HIV carries its genetic material inside a protein shell called the capsid. The virus needs this shell to deliver its genes into the nucleus of the cells it infects and to assemble new virus particles. Lenacapavir binds to the capsid proteins and disrupts several of these steps, so the virus cannot copy itself properly. What makes lenacapavir unusual is how long it lasts. After an injection, enough of the drug stays in the body to keep working for six months, and traces can remain for a year or longer. That steady level is what protects a person using it for PrEP. For treatment, a single HIV medicine is not enough on its own, because the virus can develop changes (resistance) that let it escape, which is why Sunlenca is always paired with other HIV medicines.

Dosage & Administration

Lenacapavir starts with a short loading phase so the drug reaches protective levels quickly. For Yeztugo, day 1 includes two injections and two tablets, and day 2 two more tablets. After that, a healthcare provider gives two injections every six months (26 weeks), with a window of two weeks on either side. The injections go just under the skin of the belly, or the thigh if preferred. They must be placed under the skin, not into the skin itself, which can cause serious sores. The tablets can be taken with or without food. An HIV test is done before starting and before every injection. If an injection will be more than two weeks late, the prescriber can provide weekly tablets as a bridge for up to six months. If more than 28 weeks pass since the last injection with no tablets, the start-up doses are usually repeated from day 1 after a new HIV test. Sunlenca uses the same every-six-month injections. It can be started either with an injection on day 1 plus tablets, or with tablets over two weeks before the first injection. The other HIV medicines in the regimen are still taken daily.

Side Effects

Reactions where the shot was given are by far the most common side effect. Pain, swelling, redness and a firm lump (nodule) under the skin are typical. In the prevention trials, about two in three people developed a nodule, usually around 3 cm (just over an inch) across. These lumps are often painless but slow to fade, and after the first injections they commonly lasted most of a year. Reactions tended to become less frequent with later injections, and fewer than 2 in 100 people stopped treatment because of them. Headache and nausea are the other side effects reported most often, and both were uncommon. An injection site that breaks open into a sore, or a reaction that keeps getting worse instead of settling, should be checked by the care team. In people starting Sunlenca as part of new HIV treatment, a recovering immune system can occasionally react strongly to an infection already in the body, causing new fever or other symptoms of infection. This is called immune reconstitution syndrome and should be reported to the prescriber.

Interactions & Warnings

Yeztugo carries an FDA boxed warning, the agency's most prominent kind, about drug resistance. If someone already has HIV that has not been diagnosed, lenacapavir alone cannot control it, and the virus can become resistant to lenacapavir. That is why an HIV test is required before starting and before each injection, and why fever, tiredness, muscle aches or a rash, possible signs of a new HIV infection, should be reported promptly so testing can be done. Anyone who tests positive while using Yeztugo needs to start complete HIV treatment right away. Because the drug lingers for 12 months or longer after the last injection, levels fade slowly after stopping. Someone who stops Yeztugo but is still at risk should start another form of PrEP within 28 weeks of the last injection, so they are not exposed to HIV while only low levels remain. Similarly, people stopping Sunlenca should move to another fully effective HIV regimen within 28 weeks. Yeztugo does not prevent other sexually transmitted infections (STIs), so condoms and regular STI testing remain useful. Some medicines speed up the body's breakdown of lenacapavir and can make it fail. These include rifampin (an antibiotic used for tuberculosis), the seizure medicines carbamazepine and phenytoin, and the herbal supplement St. John's wort. They must not be combined with Sunlenca, and starting one of these kinds of medicines during Yeztugo requires extra doses. Lenacapavir can also raise levels of other drugs for up to nine months after the last injection, including some cholesterol medicines (simvastatin, lovastatin), opioid pain medicines such as fentanyl and oxycodone, some blood thinners such as rivaroxaban, and some steroid medicines. Every prescriber and pharmacist should know about lenacapavir, even months after the last shot. In a large trial, pregnancies during Yeztugo use did not show more miscarriages or other problems than with Truvada, although the numbers were small. Because the risk of getting HIV rises during pregnancy, the label supports continuing PrEP. Lenacapavir passes into breast milk, but breastfed infants had very low levels and no harm was seen.

What to Expect

For prevention, lenacapavir means a visit every six months for an HIV test and injections, usually alongside testing for other sexually transmitted infections, instead of a daily pill. In two large trials, no infections occurred among more than 2,100 young women in South Africa and Uganda using it, compared with 16 among about 1,000 taking daily Truvada. Among more than 2,100 men, transgender and nonbinary people across seven countries including the US, there were 2 infections, about 89% fewer than with Truvada. It is highly effective but not perfect, and how soon full protection begins after the first dose is not known. The lump from each injection is often the most noticeable part of treatment, and a new one may appear before the previous one has fully faded. Keeping to the schedule matters more than with a daily pill, because a missed injection quietly lets drug levels fall. Planning ahead for travel or changes in insurance helps avoid gaps. For people with resistant HIV using Sunlenca, regular viral load tests (which measure the amount of HIV in the blood) show whether the combination is working. In one group of 36 people in the main trial, 72% had fewer than 50 copies per milliliter, the usual threshold for undetectable, after a year of treatment.

Questions to Ask Your Doctor

  1. 1.How does twice-yearly lenacapavir compare with daily PrEP pills or Apretude for my situation?
  2. 2.What should I do if I cannot make my next injection on time?
  3. 3.If I decide to stop, what PrEP should I switch to, and when?
  4. 4.Do any of my current medicines or supplements interact with lenacapavir, including ones I might start in the next year?
  5. 5.How should we handle the lumps at the injection site if they bother me?

Last reviewed • Oct 2026

Educational content, not medical advice.